同仁堂聚焦"满足行业需求的中药质控体系缺乏"的行业痛点，与北京中医药大学合作，在功效物质明 晰、质量控制指标筛选等方面建立了一系列专有技术和方法，系统阐明了大黄、人参等中药饮片所含的 化学成分以及体内代谢转化成分，进而精准表征了大黄蛰虫丸、人参养荣丸、人参健脾丸等中药复方的 物质基础，阐明了中药质量形成机理。通过内控标准提升和技术升级改造，促进了产品质量的进一步提 升。 近日，中华中医药学会公示了2025年度中华中医药学会科学技术奖评审结果。由北京中医药大学高晓燕 教授牵头，联合同仁堂等6家单位共同申报的《中药功效物质高效发现技术体系创新与产业化应用》项 目获科技进步三等奖。 阐明中药功效物质是构建中药整体质控标准体系、保障临床用药和产业发展的关键。几十年来，随着中 药现代化进程的发展，在中药功效成分研究领域取得了可喜进展，但依然无法克服其片面性、假阳性、 低效性等问题，制约了中药标准化和国际化。该项目是以中医药传承与创新发展的国家重大发展战略为 牵引，针对制约中药功效物质发现全面性和准确性的若干技术问题，朝向中药化学成分高效解析、功效 指标精准量化和功效物质准确辨识三个关键环节开展研究：利用高分辨质谱技术， ...

Core Viewpoint - Traditional Chinese medicine (TCM) is becoming an important force in promoting global health, with Tianyao Daren Tang Group actively participating in international cooperation and product innovation to spread TCM benefits beyond borders [1][2]. Group 1: Company Initiatives - Tianyao Daren Tang's flagship product, "Suxiao Jiuxin Wan," was registered as a prescription drug in Russia in 1997, marking it as the first Chinese patent medicine to receive such approval, which set a benchmark for TCM products entering international markets [1]. - Since 2017, Tianyao Daren Tang has established a stable partnership with Russian TCM companies, leading to the registration of various products, including the Dami Wan series and Jing Wan Hong as dietary supplements and cosmetics in Russia [2]. - The company emphasizes not only product export but also the promotion of TCM culture through international exhibitions and academic exchanges, enhancing local understanding and trust in TCM [2]. Group 2: Future Directions - Tianyao Daren Tang aims to deepen cooperation with countries in the Shanghai Cooperation Organization (SCO) in the field of TCM, focusing on clinical research, technology exchange, and mutual recognition of standards to contribute to a global health community [2][3].